Proteome-wide Profiling of Asymmetric Dimethylated Arginine in Human Breast Tumors
Journal of the American Society for Mass Spectrometry · 02.08.2023 · 34 (8) · 1692-1700
DOI: 10.1021/jasms.3c00154 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of the American Society for Mass Spectrometry, online erschienen am 18.07.2023. Verfasst von Min Ma und 6 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, University of Wisconsin─Madison, Madison, Wisconsin 53705, United States. Hauptthemen laut MEDLINE: Proteome, Breast Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIGMS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Arginine methylation catalyzed by protein arginine methyltransferases (PRMTs) is a prevalent post-translational modification (PTM) that regulates diverse cellular processes. Aberrant expression of type I PRMTs that catalyze asymmetric arginine dimethylation (ADMA) is often found in cancer, though little is known about the ADMA status of substrate proteins in tumors. Using LC-MS/MS along with pan-specific ADMA antibodies, we performed global mapping of ADMA in five patient-derived xenograft (PDX) tumors representing different subtypes of human breast cancer. In total, 403 methylated sites from 213 proteins were identified, including 322 novel sites when compared to the PhosphositesPlus database. Moreover, using peptide arrays in vitro, approximately 70% of the putative substrates were validated to be methylated by PRMT1, PRMT4, and PRMT6. Notably, when compared with our previously identified ADMA sites from breast cancer cell lines, only 75 ADMA sites overlapped between cell lines and PDX tumors. Collectively, this study provides a useful resource for both PRMT and breast cancer communities for further exploitation of the functions of PRMT dysregulation during breast cancer progression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, University of Wisconsin─Madison, Madison, Wisconsin 53705, United States.
- McArdle Laboratory for Cancer Research, University of Wisconsin─Madison, Madison, Wisconsin 53705, United States.
- Advanced Medical Research Institute, Shandong University, Shandong 250012, PR China.
- Department of Chemistry, University of Wisconsin─Madison, Madison, Wisconsin 53706, United States.
- Lachman Institute for Pharmaceutical Development, School of Pharmacy, University of Wisconsin─Madison, Madison, Wisconsin 53705, United States.
- Wisconsin Center for NanoBioSystems, School of Pharmacy, University of Wisconsin─Madison, Madison, Wisconsin 53705, United States.
ORCID-Profile: Eui-Jun Kim, Lauren Fields, Lingjun Li
Förderung
- NCI NIH HHS
- NIGMS NIH HHS
- NIH HHS
- NCRR NIH HHS
- NIDDK NIH HHS
- NIA NIH HHS
- National Cancer Institute
- Wisconsin Alumni Research Foundation
Zitieren
APA
Ma, M., Liu, F., Miles, H. N., Kim, E. J., Fields, L., Xu, W., & Li, L. (2023). Proteome-wide Profiling of Asymmetric Dimethylated Arginine in Human Breast Tumors. Journal of the American Society for Mass Spectrometry, 34(8), 1692-1700. https://doi.org/10.1021/jasms.3c00154
Vancouver
Ma M, Liu F, Miles HN, Kim EJ, Fields L, Xu W, et al. Proteome-wide Profiling of Asymmetric Dimethylated Arginine in Human Breast Tumors. Journal of the American Society for Mass Spectrometry. 2023;34(8):1692-1700. doi:10.1021/jasms.3c00154
BibTeX
@article{Ma2023,
author = {Ma, Min and Liu, Fabao and Miles, Hannah N and Kim, Eui-Jun and Fields, Lauren and Xu, Wei and Li, Lingjun},
title = {Proteome-wide Profiling of Asymmetric Dimethylated Arginine in Human Breast Tumors},
journal = {Journal of the American Society for Mass Spectrometry},
year = {2023},
volume = {34},
number = {8},
pages = {1692--1700},
doi = {10.1021/jasms.3c00154}
}
EUVIMED